Multidrug-Resistant Burkholderia cepacia, Candida dubliniensis, and Candida glabrata Infected Pancreatic Pseudocyst

Sarah Rawi ¹, Bryan Stringer ¹, Myrla Sajo ²

¹. Internal Medicine, University of Connecticut Health Center, Farmington, USA ². Internal Medicine/Infectious Disease, Saint Francis Hospital and Medical Center, Hartford, USA

Corresponding author: Sarah Rawi, rawi@uchc.edu

Abstract

Burkholderia cepacia is a gram-negative bacillus that is most commonly associated with pneumonia in the immunocompromised patients. The most common organisms associated with pancreatic infections are Escherichia coli, Klebsiella pneumoniae, Enterobacter spp., and Enterococcus spp. We report a case of a 45-year-old gentleman with recent acute pancreatitis who presented with hypoglycemia, altered mental status, worsening epigastric pain, and early satiety. He was diagnosed with a large peripancreatic infected cyst which grew multidrug-resistant (MDR) Burkholderia cepacia, Candida glabrata, and Candida dubliniensis. This case report focuses on the importance of distinguishing and recognizing risk factors for this MDR organism, in order to provide better patient care.

Categories: Internal Medicine, Gastroenterology, Infectious Disease
Keywords: burkholderia, candida, pancreatitis, resistant, infected, pseudocyst

Introduction

Pancreatic cysts have up to 13.5% prevalence and are classified between non-neoplastic and neoplastic cysts. Infected pseudocysts are non-neoplastic and are a result of complications of pancreatitis. The Atlanta classification has now revised the definition of ’pseudocyst’ as a complication of interstitial edematous pancreatitis, while ‘walled-off necrosis (WON)’ is used for patients with necrotizing pancreatitis; both arising around four weeks after acute pancreatitis. The most common organisms associated with pancreatic infections, including abscesses, are Escherichia coli, Klebsiella pneumoniae, Enterobacter spp., and Enterococcus spp. Rarely, other organisms involved are Pseudomonas aeruginosa, Staphylococcus spp., Streptococcus spp., and Bacteroides. Burkholderia cepacia is a gram-negative obligate aerobe and has been described as a pathogenic organism in humans with chronic granulomatous disease. It is also frequently described in patients with cystic fibrosis and has been associated with a worse prognosis in those who are colonized. B. cepacia is known to be susceptible to trimethoprim/sulfamethoxazole (TMP-SMX), ceftazidime, carbapenems, ureidopenicillins, fluoroquinolones, minocycline, and chloramphenicol. Antifungal agents commonly used against Candida species include echinocandins, amphotericin B, and azoles. Although frequently associated with immunocompromised hosts, Burkholderia species are emerging pathogens in healthcare settings, with cases of urinary tract infections, pneumonia, and septic arthritis sited in the literature. Thus, it is essential to continue investigating risk factors for this infection in different patient populations and to pay close attention to the cases that emerge.
Case Presentation

A 45-year-old male with a past medical history of substance abuse, hypertension, type II diabetes mellitus, and acute pancreatitis three weeks prior to admission presented to the emergency department (ED) unresponsive and hypoglycemic. His recent acute pancreatitis was presumed secondary to alcohol use, and he was discharged to a rehabilitation facility. In the rehabilitation facility, he was found minimally responsive with a glucose fingerstick of 36 mg/dL and hypoxic. In the ED, his vitals were stable, saturating 100% on 4 liters nasal cannula (4LNC), afebrile, normal rate, and normotensive. His physical exam was only remarkable for left lower lobe (LLL) rhonchi and lethargy; his abdominal exam was benign (soft, nondistended, and nontender). Chest x-ray (CXR) and CT of the chest on day of admission showed an LLL opacity (Figure 1). His laboratory results were significant for total bilirubin of 1.6 mg/dL, alanine aminotransferase (ALT) 46 U/L, aspartate aminotransferase (AST) 65 U/L, and alkaline phosphatase (AP) of 357 U/L. His lipase and amylase were within normal limits. The next morning, he exhibited a systemic inflammatory response with tachycardia, tachypnea, and was febrile to 101.3°F without a clear source. He was started on IV vancomycin and cefepime to treat an LLL pneumonia. He began endorsing epigastric abdominal pain, back pain, and early satiety.

FIGURE 1: Chest x-ray on admission demonstrating a left lower lobe opacity.

Thus, on day 2 he underwent CT of the abdomen and pelvis (A/P). The CT A/P demonstrated an 18.5 x 10.3 cm large cystic mass compatible with a pseudocyst containing debris, thought to be a complication from his recent pancreatitis (Figure 2) [1]. He also had a moderate left and small right pleural effusion. On day 7 of admission, his blood cultures from admission grew *Burkholderia cepacia* sensitive to ceftazidime, meropenem, and TMP-SMX. It was resistant to
amikacin, cefepime, ciprofloxacin, gentamicin, and piperacillin-tazobactam. The patient was transitioned to ceftazidime.

![CT scan of the abdomen and pelvis showing a peripancreatic cyst](image)

FIGURE 2: CT of the abdomen and pelvis showing an 18.5 x 10.3 cm peripancreatic cyst containing debris, most consistent with a pancreatic pseudocyst.

Due to persistent fevers on the 10th day of admission, ultrasound-guided right-sided thoracentesis was performed and 800 mL of exudative, culture negative, fluid was removed. The patient's abdominal pain and distention persisted. He underwent CT-guided drainage of his presumed pseudocyst on day 11 and 60 mL of serous fluid was aspirated. The culture grew multidrug-resistant (MDR) *B. cepacia*, rare *Candida dubliniensis*, and rare *Candida glabrata*. Micafungin was added. *B. cepacia* had the same susceptibility pattern compared to the blood culture isolate. Despite the CT-guided drainage, the patient's clinical condition worsened. This led to a cyst gastrostomy with AXIOS stent (Boston Scientific, Marlborough, MA) placement via endoscopic ultrasound (EUS) on day 15 of admission. During the procedure, a single segmental biliary stricture was found in the lower and middle third of the main bile duct, which did not allow for a complete endoscopic retrograde cholangiopancreatography (ERCP). The drained fluid was cultured and continued to grow MDR *B. cepacia*, with the same susceptibility pattern, and its cytology was negative for malignant cells.

Two weeks later, a repeat ERCP resulted in a biliary sphincterotomy with stent placement and removal of the previously placed AXIOS stent. Repeat CT A/P two weeks after the ERCP and one month after starting antibiotics showed a decrease in the size of the cyst to 8.5 x 3.2 cm (Figure
Ceftazidime and micafungin were continued for a total of 10 weeks. Despite prolonged parenteral antimicrobial therapy, the patient had recurrent symptoms and growth of his pseudocyst. Four months after his diagnosis of pancreatitis, he eventually required definitive surgical intervention with exploratory laparotomy and open cyst gastrostomy. Intraoperative findings showed a large pancreatic pseudocyst filled with pus and necrotic pancreas. This finally led to a more favorable outcome with complete eradication of infection.

**Discussion**

This was a unique case of a common complication of pancreatitis. Although infected pseudocysts are associated with mixed anaerobes and aerobes, *B. cepacia* has not been reported. The infected pseudocyst in this case rapidly progressed and caused severe clinical symptoms. It is important to note that the patient had persistent fevers which led to continuation of further investigation and later on, showing the need for drainage of the infected pseudocyst. It is essential to recognize that the patient’s symptoms did not completely resolve until he had adequate drainage and surgical intervention. This demonstrated that antibiotics alone are not effective in eradicating large infected pseudocysts. Moreover, the patient’s exudative pleural
fluid was likely reactive secondary to the inflammatory state of the pancreas, a very common phenomenon. Instead of considering two unique processes in this patient, his sepsis from presentation could have been secondary to his infected *B. cepacia* pancreatic pseudocyst and bacteremia.

As *B. cepacia* is not a typical member of human’s gastrointestinal microbiota, we must consider iatrogenic introduction of this bacteria in our case. *B. cepacia* is typically a soil-dwelling bacterium, but is also a common colonizer in fluids in the hospital setting [9]. Interestingly, around the time of the case we present, the CDC released a report of a multistate outbreak of *Burkholderia* associated with contaminated hand foam [10]. Another epidemiologic investigation discovered 20 cases of healthcare-associated transmission of *Burkholderia* secondary to contaminated nasal spray at an ear-nose-throat (ENT) clinic [11]. After receiving treatment at two different hospitals, it is unclear how this bacterium was introduced to our patient. As far as we know, this was an isolated case, but with the bacteria isolated being multidrug resistant and with the emergence of these species, we must remain vigilant to promptly recognize patterns of contamination [12]. As this patient was immunocompetent, there was question if this patient’s intravenous drug abuse (IVDA) history had a role in acquiring this organism [1].

**Conclusions**

This case shows the importance and value in including uncommon MDR organisms in the differential for infected pseudocysts for more efficient and accurate management. IVDA may be a risk factor to consider when deciding appropriate antibiotic coverage in a patient who presents with fevers and a large pancreatic pseudocyst. However, surgical intervention and/or drainage is critical for eradication of organisms in large cysts, as seen in this patient case. Future opportunities of research lie in evaluating risk factors for *B. cepacia* infections, its prevalence, and how to best manage it in unexpected sites.

**Additional Information**

**Disclosures**

**Human subjects:** Consent was obtained by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

**References**

1. Rawi S, Mago S: Multi-drug resistant Burkholderia cepacia infected pancreatic pseudocyst. Am J Gastroenterol. 2019, 114:S727-S728. 10.14309/01.ajg.0000594764.41930.17
2. Elta GH, Enestvedt BK, Sauer BG, Lennon AM: ACG clinical guideline: diagnosis and management of pancreatic cysts. Am J Gastroenterol. 2018, 113:464-479. 10.1038/ajg.2018.14
3. Thoeni RF: The revised Atlanta classification of acute pancreatitis: its importance for the radiologist and its effect on treatment. Radiology. 2012, 262:751-764. 10.1148/radiol.11110947
4. Sabater-Orti L, Calvete-Chornet J, Lledó-Matoses S: Therapeutic approach to pancreatic abscess. Clinical Pancreatology: For Practising Gastroenterologists and Surgeons. Domínguez-Muñoz, JE, Malfertheiner, P (ed): Wiley-Blackwell Publishing Ltd, Oxford, UK; 2004. 1:149-155. 10.1002/9780470987506.ch17
5. Johnston RB Jr: Clinical aspects of chronic granulomatous disease. Curr Opin Hematol. 2001,
6. Coenye T, Vandamme P, Govan JRW, LiPuma JJ: Taxonomy and identification of the
Burkholderia cepacia complex. J Clin Microbiol. 2001, 39:3427-3436. 10.1128/jcm.39.10.3427-3436.2001

7. Burkholderia cepacia complex. (2017). Accessed: January 30, 2020:
http://www.antimicrobe.org/b19.asp.

8. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious
Diseases Society of America. (2016). Accessed: April 21, 2020:
https://www.idsoociety.org/practice-guideline/candidiasis/.

9. Baul SN, De R, Mandal PK, Roy S, Dolai TK, Chakrabarti P: Outbreak of Burkholderia cepacia
infection: a systematic study in a hematol- oncology unit of a tertiary care hospital from
Eastern India. Mediterr J Hematol Infect Dis. 2018, 10:e2018051. 10.4084/mjhid.2018.051

10. Multistate outbreak of Burkholderia cepacia complex infections associated with the use of
Medline Remedy Essentials No-Rinse Cleaning Foam. (2016). Accessed: December 7, 2019:
http://www.cdc.gov/hai/outbreaks/b-cepacia/no-rinse.html.

11. Tran D, Cassidy M, Buehring T, Pierce R: 1253. Healthcare-associated transmission of
Burkholderia cepacia complex associated with extrinsically contaminated nasal spray. Open
Forum Infect Dis. 2018, 5:S381-S382. 10.1093/ofid/ofy210.1086

12. Rhodes KA, Schweizer HP: Antibiotic resistance in Burkholderia species. Drug Resist Updat.
2016, 28:82-90. 10.1016/j.drup.2016.07.003